|By PR Newswire||
|February 28, 2014 02:45 AM EST||
UPPSALA, Sweden, February 28, 2014 /PRNewswire/ --
The Swedish pharmaceutical company Oasmia Pharmaceutical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has conditionally approved Paccal Vet® CA-1 (paclitaxel for injection), providing veterinary oncologists with a new treatment option in the battle with canine mammary carcinoma and squamous cell carcinoma.
Paccal Vet CA-1 is the first veterinary drug to utilize paclitaxel, one of the most frequently used chemotherapeutics for the treatment of a wide range of cancers in humans for the past 20 years. Oasmia has signed an agreement with the global pharmaceutical company Abbott which gives its Animal Health division the exclusive worldwide distribution rights to Paccal Vet CA-1, excluding Russia, Japan and the Commonwealth of Independent States (CIS).
"The conditional approval of Paccal Vet CA-1 is a big step forward for veterinary cancer treatment," commented Julian Aleksov, chief executive officer of Oasmia. "In addition, it confirms the potential of our unique patented drug delivery technology, XR-17 - a novel derivative of vitamin A that we will be using in clinical trials with our other compounds for a number of human and veterinary indications."
"Pets are living longer and owners increasingly desire a 'human level of care' for serious and chronic conditions," said Andrea Wainer, divisional vice president and general manager, Abbott Animal Health. "With the FDA conditional approval of Paccal Vet CA-1 we are able to offer veterinarians and pet owners a trusted cancer therapy used to treat millions of people each year."
Cancer accounts for nearly 50 percent of all deaths in dogs 10 years of age or older. It is the leading cause of canine disease-related deaths, with up to three million new cases diagnosed annually worldwide.
Canine squamous cell carcinoma, a type of skin cancer, is a malignant tumor of epidermal cells which is often developed in the oral and nasal cavities and on the paws. Light-skinned and short-haired dogs who spend a long time in the sunshine have a higher risk of squamous cell carcinoma.
Mammary tumors are the most common tumor in female dogs that have not been spayed, affecting one out of every four.
For more information, please contact:
Mikael Widell, Vice President Communications
E-mail: [email protected]
Ask someone to architect an Internet of Things (IoT) solution and you are guaranteed to see a reference to the cloud. This would lead you to believe that IoT requires the cloud to exist. However, there are many IoT use cases where the cloud is not feasible or desirable. In his session at @ThingsExpo, Dave McCarthy, Director of Products at Bsquare Corporation, will discuss the strategies that exist to extend intelligence directly to IoT devices and sensors, freeing them from the constraints of ...
Oct. 1, 2016 11:45 AM EDT Reads: 2,791
Oct. 1, 2016 11:30 AM EDT Reads: 1,322
Oct. 1, 2016 11:15 AM EDT Reads: 871
Oct. 1, 2016 10:45 AM EDT Reads: 605
Oct. 1, 2016 10:30 AM EDT Reads: 710
Oct. 1, 2016 10:30 AM EDT Reads: 1,724
Oct. 1, 2016 10:00 AM EDT Reads: 3,198
Oct. 1, 2016 10:00 AM EDT Reads: 606
Oct. 1, 2016 10:00 AM EDT Reads: 4,672
Oct. 1, 2016 10:00 AM EDT Reads: 519
Oct. 1, 2016 10:00 AM EDT Reads: 3,321
Oct. 1, 2016 09:45 AM EDT Reads: 2,769
Oct. 1, 2016 09:45 AM EDT Reads: 835
Oct. 1, 2016 09:15 AM EDT Reads: 1,677